Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05849298CT.gov A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | — | Active Not Recruiting | — | — | — |
NCT04720157CT.gov An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | — | Active Not Recruiting | — | — | — |
NCT04633252CT.gov A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04523207CT.gov A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | — | Completed | — | — | — |
NCT04248621CT.gov Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients | — | Unknown | — | — | — |
NCT03587285CT.gov A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer | — | Unknown | — | — | — |
NCT00298155CT.gov Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer | — | Completed | — | — | — |
NCT00167648CT.gov Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Goserelin (this asset) | Novartis Pharmaceuticals | Approved | BB · 66 |
| Docetaxel | Merck Sharp & Dohme LLC | P4 | BBB |
| Prednisone | Merck Sharp & Dohme LLC | P3 | BBB |
| Degarelix | Novartis Pharmaceuticals | P4 | BBB |
| Leuporelin | Dana-Farber Cancer Institute | P4 | BB |
| Abiraterone | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Radium Ra-223 | Bayer | P3 | BB |
| Prednisolone | Eli Lilly and Company | P3 | BB |
| Gozetotide | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
+42 more in the Prostate Neoplasm cohort
Other indications for Goserelin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 70 |
| Prostate Carcinoma | — | P3 | BB · 69 |
| Prostate Adenocarcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Goserelin in Prostate Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/goserelin-prostate-neoplasm-103702
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →